Fenwick has advised Scribe Therapeutics. Latham & Watkins has advised the underwriters. Scribe Therapeutics Inc., a clinical-stage biotechnology company specializing in in vivo CRISPR technologies, has...
Scribe Therapeutics Completes $155.51 Million Initial Public Offering and Private Placement
Remix Therapeutics and Passage Bio Announce Merger and $100 Million Private Placement
Latham & Watkins LLP has advised Remix Therapeutics. Fenwick & West LLP has advised Passage Bio. Cooley LLP has advised Goldman Sachs & Co. LLC, Jefferies...
Slice Global Equity Secures $25 Million Series A Funding
Fenwick & West has advised Slice Global Equity. Slice Global Equity, a startup focused on equity compliance and management, has completed a $25 million Series A...
BioAge Labs Completes $115 Million Upsized Public Offering
Fenwick & West has advised BioAge Labs, Inc. Cooley LLP has represented the underwriters. BioAge Labs, Inc., a clinical-stage biopharmaceutical company (Nasdaq: BIOA), has completed an...
Juvena Therapeutics Secures $33.5 Million in Series B Financing
Fenwick & West and Wilson Sonsini Goodrich & Rosati have advised Juvena Therapeutics. Juvena Therapeutics, a clinical-stage biotechnology company, has raised $33.5 million in a Series...
EpiBiologics Secures $107 Million in Series B Funding to Advance Antibody Pipeline
Fenwick & West has advised EpiBiologics. EpiBiologics, a company specializing in tissue-selective extracellular protein degradation, has completed a $107 million Series B financing round. The funding...
Umoja Biopharma’s $100 Million Series C Financing Round
Fenwick & West represented Umoja Biopharma in the transaction. Umoja Biopharma, Inc., a developer of in vivo cell therapies that aim to realize the full reach...
BioAge Labs’ $238 Million Upsized Initial Public Offering
Fenwick & West represented BioAge Labs, Inc. in the offering, and Cooley represented the underwriters. BioAge Labs, Inc. (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic...
Blackstone and Vista Equity Partners’ $8.4 Billion Acquisition of Smartsheet
Fenwick & West is representing Smartsheet on the transaction, while Kirkland & Ellis and Simpson Thacher & Bartlett are representing Blackstone and Vista Equity Partners. Smartsheet...
Stoke Therapeutics’ $125 Million Upsized Common Stock Offering
Fenwick & West advised Stoke Therapeutics on the offering, Wilson Sonsini Goodrich & Rosati advised Stoke on IP matters and Davis Polk & Wardwell advised the...
Third Harmonic Bio’s $213.1 Million IPO
Fenwick represented Third Harmonic Bio, Inc. on the deal. Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT...
Impel NeuroPharma’s $80 Million Initial Public Offering
Fenwick & West LLP advised Impel NeuroPharma on the deal. Impel NeuroPharma, a late-stage pharmaceutical company developing transformative therapies for diseases of the central nervous system, announced its...